Coronary Vasospastic Angina: Current Understanding and the Role of Inflammation

Area of Science:

• Cardiology
• Pathophysiology
• Vascular Biology

Background:

• Coronary vasospastic angina (CVsA) is a significant cause of myocardial ischemia, encompassing stable angina, acute coronary syndromes, and sudden cardiac death.
• Inflammation, affecting the endothelium or adventitia, can lead to endothelial dysfunction.
• Endothelial dysfunction promotes vascular smooth muscle hypercontraction via Rho-kinase, precipitating clinical events.

Purpose of the Study:

• To elucidate the pathophysiology of coronary vasospastic angina (CVsA).
• To explore the interplay between inflammation, endothelium, and smooth muscle cells in CVsA.
• To evaluate potential therapeutic strategies beyond conventional treatments.

Main Methods:

• Review of existing literature on CVsA pathophysiology.
• Analysis of the roles of inflammation, endothelial function, and smooth muscle cell activity.
• Consideration of pharmacological interventions including anti-inflammatory agents.

Main Results:

• Understanding the interactions between inflammation, endothelium, and smooth muscle cells offers new insights into CVsA pathophysiology.
• Rho-kinase pathway activation is implicated in vascular smooth muscle hypercontraction.
• Anti-inflammatory treatment shows potential benefit in refractory CVsA cases.

Conclusions:

• CVsA pathophysiology involves a complex interplay of inflammatory processes and vascular cell dysfunction.
• While calcium channel blockers, nitrates, and fasudil are established treatments, anti-inflammatory therapies may offer additional benefits for select patients.
• Further investigation is required to fully understand and manage recurrent CVsA.